Metagenomi Therapeutics, Inc. (MGX)
0.934
-0.09
(-8.43%)
USD |
NASDAQ |
Oct 13, 14:03
Metagenomi Therapeutics Shareholders Equity (Quarterly) : 112.57M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 112.57M |
| March 31, 2026 | 137.78M |
| December 31, 2025 | 158.60M |
| September 30, 2025 | 178.45M |
| June 30, 2025 | 195.83M |
| March 31, 2025 | 212.66M |
| December 31, 2024 | 234.86M |
| September 30, 2024 | 255.77M |
| Date | Value |
|---|---|
| June 30, 2024 | 269.42M |
| March 31, 2024 | 275.63M |
| December 31, 2023 | 215.17M |
| September 30, 2023 | 231.74M |
| June 30, 2023 | |
| March 31, 2023 | |
| December 31, 2022 | 271.68M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 465.53M |
| Oncolytics Biotech, Inc. | -6.167M |
| Sangamo Therapeutics, Inc. | -18.96M |
| Sarepta Therapeutics, Inc. | 1.528B |
| Anixa Biosciences, Inc. | 14.47M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 173.70M |
| Total Liabilities (Quarterly) | 61.13M |
| Debt to Equity Ratio | 0.3351 |
| Current Ratio | 4.504 |
| Net Debt Paydown Yield | 2.99% |